^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR17 (MicroRNA 17)

    i
    Other names: MIR17, MicroRNA 17, Hsa-MiR-17-5p, Hsa-MiR-17-3p, Hsa-Mir-17, Hsa-Mir-17-P1a, MIMAT0000070, MIMAT0000071, MI0000071, MIR17-5p, MiR17-3p, MiRNA17, MiRNA91, RF00051, MIRN17, MIRN91, MiR-17, MIR91
    10d
    Gastric Cancer Epithelial-Mesenchymal Transition-The Role of Micro-RNA. (PubMed, Cancers (Basel))
    Several EMT-related miRNAs show consistent associations with invasion, metastasis, peritoneal dissemination, prognosis, and chemoresistance, and many are detectable in circulation. Overall, EMT-related miRNAs orchestrate gastric cancer cell plasticity and tumor-microenvironment crosstalk and represent promising biomarker and therapeutic candidates that warrant validation in prospective, subtype-stratified, and translational studies.
    Review • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • TGFB1 (Transforming Growth Factor Beta 1) • MIR192 (MicroRNA 192) • MIR27A (MicroRNA 27a) • MIR17 (MicroRNA 17) • MIR23A (MicroRNA 23a) • MIR375 (MicroRNA 375) • MIR506 (MicroRNA 506) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • MIR106B (MicroRNA 106b) • MIR130A (MicroRNA 130a) • MIR148A (MicroRNA 148a) • MIR150 (MicroRNA 150) • MIR181A1 (MicroRNA 181a-1) • MIR200 (MicroRNA 200) • MIR204 (MicroRNA 204) • MIR218 (MicroRNA 218) • MIR26A1 (MicroRNA 26a-1) • MIR30A (MicroRNA 30a)
    21d
    Carnosol enhances radiosensitivity in NSCLC cells by targeting the miR-17-5p/TOLLIP/NF-κB Axis. (PubMed, Toxicol Res (Camb))
    miR-17-5p mimics partially reversed these effects. Carnosol may exert its radiosensitizing effect in NSCLC by targeting the miR-17-5p/TOLLIP/NF-κB axis and disrupting DNA repair, highlighting its therapeutic potential in overcoming radioresistance.
    Journal
    |
    RAD51 (RAD51 Homolog A) • TLR4 (Toll Like Receptor 4) • MIR17 (MicroRNA 17) • NFKBIA (NFKB Inhibitor Alpha 2)
    21d
    Significance of MALAT1 long non-coding RNA and miR-20a-5p in regulating epithelial mesenchymal transition in luminal breast cancer patients. (PubMed, J Egypt Natl Canc Inst)
    Our findings suggest that miR-20a-5p plays an oncogenic role in luminal breast cancer by promoting EMT, while MALAT1 may contribute to disease progression through indirect regulatory mechanisms. Finally, MALAT1 and miR-20a-5p might serve as potential therapeutic and prognostic targets in LBC.
    Journal
    |
    CDH1 (Cadherin 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • MIR135B (MicroRNA 135b) • MIR17 (MicroRNA 17) • SNAI1 (Snail Family Transcriptional Repressor 1) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2) • MIR20A (MicroRNA 20a) • MIR93 (MicroRNA 93)
    26d
    Liquid biopsy in triple-negative breast cancer: a promising tool for diagnosis, prognosis, and treatment monitoring. (PubMed, Front Oncol)
    This review provides a comprehensive overview of the current and future applications of liquid biopsy in TNBC management, highlighting its potential to improve early disease detection, optimize therapeutic strategies, and refine patient classification. Integrating liquid biopsy into routine clinical practice could lead to better treatment outcomes and more personalized approaches to TNBC care.
    Review • Journal • Liquid biopsy
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MIR17 (MicroRNA 17) • MIR105 (MicroRNA 105) • MIR19A (MicroRNA 19a)
    |
    TP53 mutation • PIK3CA mutation
    26d
    Targeted Inhibition of Oncogenic microRNAs miR-21, miR-17, and miR-155 Suppresses Tumor Growth and Modulates Immune Response in Colorectal Cancer. (PubMed, Pharmaceutics)
    Importantly, therapeutic responses in vivo substantially exceeded predictions based on in vitro tumor cell proliferation and motility measurements, revealing critical contributions of systemic immunomodulation. These findings demonstrate that miRNA inhibition reshapes tumor-immune interactions, positioning anti-miRNA therapeutics as immunomodulatory agents for effective colorectal cancer treatment.
    Journal
    |
    MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21) • MIR17 (MicroRNA 17)
    1m
    Upregulation of a MicroRNA Signature Involving miR-17-5p, miR-26b-5p, miR-106a-5p, and miR-146a-5p During Cervical Epithelial Transformation. (PubMed, Epigenomes)
    The gradual increase in specific miRNAs with lesion severity and HPV infection suggests their role in cervical carcinogenesis. The identified miRNAs may serve as promising non-invasive biomarkers for early detection and monitoring of HPV-associated cervical lesions.
    Journal
    |
    MIR155 (MicroRNA 155) • MIR106A (MicroRNA 106a) • MIR17 (MicroRNA 17) • MIR191 (MicroRNA 191) • MIR29A (MicroRNA 29a)
    1m
    The Role of microRNAs as Potential Biomarkers in Diffuse Large B-Cell Lymphoma. (PubMed, Noncoding RNA)
    While novel therapies such as rituximab and polatuzumab vedotin have led to improved outcomes, approximately 35% of patients eventually develop relapsed or refractory disease. Among these, miR-155 and miR-21 are particularly well studied, playing central roles in both tumor progression and remodeling of the tumor microenvironment. This review summarizes current evidence on the biological and clinical relevance of miRNAs in DLBCL, emphasizing their diagnostic and prognostic potential.
    Review • Journal
    |
    MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21) • MIR17HG (MiR-17-92a-1 Cluster Host Gene) • MIR34A (MicroRNA 34a-5p) • MIR17 (MicroRNA 17) • MIR181A1 (MicroRNA 181a-1) • MIR124-3 (MicroRNA 124-3)
    |
    Rituxan (rituximab) • Polivy (polatuzumab vedotin-piiq)
    2ms
    MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma. (PubMed, bioRxiv)
    In the myoblast model system, transduction studies with exogenous miR-17-92 or miRNA-sponge expression constructs indicated that miR-17-92 is necessary but not sufficient for oncogenic transformation. Together, these findings establish a cooperative transcriptional axis in FP-RMS involving P3F and MYCN that activates MIR17HG through a distal regulatory element, thereby contributing to oncogenic behavior and uncovering a novel mechanistic vulnerability.
    Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MIR17HG (MiR-17-92a-1 Cluster Host Gene) • MIR17 (MicroRNA 17) • MIR92A1 (MicroRNA 92a-1) • PAX3 (Paired Box 3) • PAX7 (Paired Box 7)
    |
    MYCN expression
    2ms
    MicroRNA Signatures and Machine Learning Models for Predicting Cardiotoxicity in HER2-Positive Breast Cancer Patients. (PubMed, Pharmaceuticals (Basel))
    Background: HER2-positive breast cancer patients receiving chemotherapy and targeted therapy (including anthracyclines and trastuzumab) face an elevated risk of cardiotoxicity, which can lead to long-term cardiovascular complications... Circulating miRNAs show promise as biomarkers for predicting cardiotoxicity in breast cancer patients. Machine learning approaches may enhance miRNA-based risk stratification, enabling personalized monitoring and early cardioprotective interventions.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • MIR155 (MicroRNA 155) • MIR199A1 (MicroRNA 199a-1) • MIR143 (MicroRNA 143) • MIR17 (MicroRNA 17) • MIR199A (MicroRNA 199a) • miR-185 (MicroRNA 185) • MIR124-2 (MicroRNA 124-2) • MIR133B (MicroRNA 133b) • MIR145 (MicroRNA 145) • MIR124-3 (MicroRNA 124-3)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab)
    2ms
    Reversing the Irreversible: miRNA-Targeting Mesyl Phosphoramidate Oligonucleotides Restore Sensitivity to Cisplatin and Doxorubicin of KB-8-5 Epidermoid Carcinoma Cells. (PubMed, Biomedicines)
    miRNA-targeted mesyl phosphoramidate oligonucleotides are effective tools for overcoming resistance to the clinically approved chemotherapeutics cisplatin and doxorubicin. The relationship between miR-21, miR-17, and miR-155 and the novel MDR markers such as SEH1L, TUBA4A, and ZYX was revealed, thereby expanding the current understanding of the molecular mechanisms underlying tumor cell resistance to chemotherapy.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21) • MIR17 (MicroRNA 17)
    |
    cisplatin • doxorubicin hydrochloride
    2ms
    Decoding the relationships among miRNA, HPV infection, and tumor suppressor gene expression in breast cancer patients. (PubMed, Sci Rep)
    A weak negative correlation between PTEN and three miRNAs, and weak positive correlations between CCND1 and miR-106b-5p and also TP53 and miR-20a-5p were observed. These findings emphasize the potential role of HPV and related biomarkers in the progression of breast cancer, indicating avenues for further research and therapeutic strategies.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • CCND1 (Cyclin D1) • MIR17 (MicroRNA 17) • MIR106B (MicroRNA 106b) • MIR20A (MicroRNA 20a)
    2ms
    Exosomal miR-17 Drives Thyroid Cancer Lung Metastasis via NF-κB Activation. (PubMed, Oncol Res)
    Animal experiments confirmed its role in promoting tumor growth and lung metastasis. Exosomal miR-17-5p remodels the pulmonary microenvironment into a pro-inflammatory niche, facilitating thyroid cancer colonization and offering a potential therapeutic target.
    Journal
    |
    IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • MIR17 (MicroRNA 17)